Remove 2014 Remove Drug Development Remove Drug Pricing
article thumbnail

The unsustainability of clinical trials and need for transformative change

Pharmaceutical Technology

The present clinical trial ecosystem is not equipped nor projected to have the capacity to satisfy this demand, and as a result the ecosystem is facing a potential slowdown in drug development. According to a November 2024 GlobalData report, per-trial costs have risen steadily since 2014, with single country trials increasing by 2.9%

article thumbnail

Incyte replaces CEO Hoppenot with dealmaker Meury

BioPharma Dive

The company now owns six other approved drugs, including a cream formulation of Jakafi’s main ingredient that’s proved useful treating atopic dermatitis and vitiligo. Hervé joined Incyte in 2014 when it was a single product, U.S.-only only company,” said board member Baker, in a statement. billion today.”

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

September 2023 Newsletter

Safe Biologics

Pitts: The IRA makes the risks of developing new drugs too high On September 14th, an op-ed by former FDA Associate Commissioner Peter J. Pitts ran in the Pittsburgh Post-Gazette, in which he highlighted his concerns with Medicare drug price-setting policies stemming from the Inflation Reduction Act (IRA), passed last year.

article thumbnail

The golden era of GLP-1 drugs: How will it impact medicine and society?

BioPharma Dive

Deep Dive Library Events Press Releases Topics Sign up Search Sign up Search Pharma Biotech FDA Clinical Trials Deals Drug Pricing Gene Therapy An article from Sponsored The golden era of GLP-1 drugs: How will it impact medicine and society? You can unsubscribe at anytime. The implications of this shift are profound.